Tuesday, Repligen Corporation (NASDAQ:RGEN) reported second-quarter sales of $154.1 million, almost in line with the consensus estimate of $154.12 million. The company reported second-quarter adjusted gross margin of 49.6% compared to 50.2% a year ago. The adjusted operating margin fell from 18.5% to 10.1%, and the EBITDA margin was 15.2%, down from 24.2% a year ago. Tony J. Hunt, CEO of Repligen, said, “We delivered solid second-quarter revenue of $154 million and first-half revenue of $305 million, achieving our year-to-date sales target. We are very encouraged by orders in the quarter, with continued strength in Pharma demand and a pickup in CDMO activity. New modalities continued to show strong year-over-year momentum in both revenue and orders.” The company reported an adjusted EPS of 33 cents, which is in ...